Page 8 - HFA Dateline 2020-2021 Special Issue

COMPARED TO GENE THERAPY
While the process is similar to what you have heard about gene
therapy for hemophilia, it is significantly different in the sense that
it uses a completely different viral vector and therefore would not
interfere with you having access to gene therapy in the future. Other
parameters in your health profile might keep you from getting gene
therapy for hemophilia, but it won’t be because you had the vaccine.

The Johnson & Johnson vaccine uses an adenovirus, which is
altered to create the protein spike. Gene therapy being studied for
hemophilia treatment uses an adeno-associated virus (AAV). Even
though they sound the same, these two types of viruses are different
and are not related, and having a Johnson & Johnson adenovirus
vaccine will not cause you to create antibodies to an AAV.

SO, LET'S

BUST SOME

MYTHS:

Getting an mRNA vaccine will
prevent you from being able to
receive future bleeding disorder
treatments that use mRNA.
There is no evidence that having
an mRNA vaccine will close off
access to future bleeding disorder
treatments that use mRNA. The
mRNA from the vaccine goes in
and gives instructions to make the Getting a viral vector vaccine
SARS-CoV-2 spike protein and will prevent you from being
then is degraded in about 24 hours. able to receive future bleeding
disorder gene therapy treatments.
There is no evidence that having
a gene therapy vaccine made
from an adenovirus will close off
access to future gene therapy
bleeding disorder treatments
that use AAV.

8 DATELINE FEDERATION < www.hemophiliafed.org